AIM
XENT

Acrospire Investment Management’s Intersect ENT, Inc XENT Stock Holding History

Acrospire Investment Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-800
Closed -$22K – 1669
2017
Q2 		$22K Sell
800
-1,600
-67% -$36.2K 0.02% 1483
2017
Q1 		$41K Buy
+2,400
New +$33.6K 0.03% 1125

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acrospire Investment Management's XENT Position: Q3 2017 in Review

Acrospire Investment Management sold out of Intersect ENT, Inc (XENT) in Q3 2017, closing a stake of 800 shares — an estimated $22K sold.

Acrospire Investment Management first reported a position in XENT in Q1 2017 and held it in 2 quarters. The position peaked at $41K in Q1 2017. 140 funds tracked by Wall St. Rank hold XENT as of Q3 2017.

  • Acrospire Investment Management reported no remaining Intersect ENT, Inc position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 800 Intersect ENT, Inc shares in Q3 2017, an estimated $22K.
  • Acrospire Investment Management first reported a position in Intersect ENT, Inc in Q1 2017 and held it in 2 quarters.
  • Acrospire Investment Management's Intersect ENT, Inc position peaked at $41K in Q1 2017.
  • 140 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.